Back to Search
Start Over
[Expression and clinical significance of beta-catenin in multiple myeloma].
- Source :
-
Ai zheng = Aizheng = Chinese journal of cancer [Ai Zheng] 2007 Sep; Vol. 26 (9), pp. 1010-4. - Publication Year :
- 2007
-
Abstract
- Background & Objective: beta-catenin is the pivotal regulator in Wnt pathway and in charge of cellular adhesion and signal conduction. Overexpression of beta-catenin has been observed in various human tumors. This study was to investigate the expression and clinical significance of beta-catenin in multiple myeloma (MM).<br />Methods: Reverse transcription-polymerase chain reaction (RT-PCR) and Western blot were used to detect mRNA and protein expression of beta-catenin in bone marrow samples from 12 newly diagnosed MM patients, 14 relapsed/refractory MM patients, and 11 healthy donors. The clinical data and treatment outcomes of the MM patient were also analyzed.<br />Results: The positive rate and the expression level of beta-catenin mRNA were significantly lower in healthy donors than in newly diagnosed patients and relapsed/refractory patients (27.3% vs. 75.0% and 100%, P=5.01e(-4); 0.35+/-0.17 vs. 0.72+/-0.11 and 0.85+/-0.16, P=5.88e(-5)); the mRNA level of beta-catenin was significantly lower in newly diagnosed patients than in relapsed/refractory patients (P=0.045). beta-catenin protein was not detected in healthy donors; while the positive rate and the expression level of beta-catenin protein were significantly lower in newly diagnosed patients than in relapsed/refractory patients (50.0% vs. 85.7%, 0.32+/-0.11 vs. 0.21+/-0.08, P=0.039). In the 10 newly diagnosed MM patients with evaluable treatment outcomes, the positive rate of beta-catenin protein was significant lower in the 7 patients without response than in the 3 patients showed response (14.3% vs. 100%, P=0.033). The positive rate of beta-catenin protein was significant higher in the 16 Durie/Salmon stage III patients than in the 10 stage II patients (87.5% vs. 40.0%, P=0.026), and significant higher in ISS stage III patients than in stage I and II patients (100% vs. 45.5% and 33.3%, P=0.006, P=0.032). The protein level of beta-catenin was positively correlated to serum levels of beta2-MG (r=0.688, P=0.002) and lactate dehydrogenase (LDH) (r=0.502, P=0.034).<br />Conclusion: The expression of beta-catenin is related with treatment outcome, Durin-Salmon stage and ISS stage of MM, and is positively correlated to serum levels of LDH and beta2-MG.
- Subjects :
- Adult
Aged
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Female
Humans
Male
Middle Aged
Multiple Myeloma blood
Multiple Myeloma therapy
Neoplasm Recurrence, Local
Neoplasm Staging
Prognosis
RNA, Messenger metabolism
Remission Induction
beta Catenin genetics
L-Lactate Dehydrogenase blood
Multiple Myeloma metabolism
Multiple Myeloma pathology
beta 2-Microglobulin blood
beta Catenin metabolism
Subjects
Details
- Language :
- Chinese
- Volume :
- 26
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Ai zheng = Aizheng = Chinese journal of cancer
- Publication Type :
- Academic Journal
- Accession number :
- 17927863